ArticleInternational journal of clinical oncology2022
Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050.
Article in International journal of clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
152 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Estimates of the global burden of HIV-attributable and all-cause AIDS-defining cancers: a population-based modeling study.Frontiers in public health · 2026Pooled it
- Comparison of Single Versus Multiple Nonpharmacological Interventions for the Management of Lung Cancer-Related Fatigue: A Systematic Review.The clinical respiratory journal · 2025Pooled it
- Facilitators and barriers of lung cancer screening participation: umbrella and systematic review of the global evidence.BMC public health · 2025Pooled it
- Comparative safety and efficacy of tislelizumab-based regimens versus chemotherapy in lung cancer: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Supportive eHealth Technologies and Their Effects on Physical Functioning and Quality of Life for People With Lung Cancer: Systematic Review.Journal of medical Internet research · 2024Pooled it
- Lung cancer mortality and associated predictors: systematic review using 32 scientific research findings.Frontiers in oncology · 2023Pooled it
- The Relationship Between Illness Uncertainty and Social Support Among Cancer Patients: A Meta-analysis.Cancer nursingPooled it
- Geographic disparities and health inequality evolution in the disease burden of tracheal, bronchus, and lung cancer in Asia: a 33-year longitudinal analysis and future projections.Annals of medicine · 2026Article
- Prognostic Value of the Lung Immune Prognostic Index in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab: A Real-World Analysis Beyond PD-L1 Expression.Diagnostics (Basel, Switzerland) · 2026Article
- MOF promotes venous thromboembolism in lung cancer by activating the YBX1-MALT1-NF-κB-PAI-1 axis, possibly through histone crotonylation.The Journal of biological chemistry · 2026Article
- The hsa_circ_0084050/miR-373-3p Axis Controls Bone Sialoprotein-Induced ADAM9 Upregulation to Drive Lung Cancer Progression and Metastasis.International journal of molecular sciences · 2026Article
- Experimental evaluation of Nilotinib and Paclitaxel co-delivered via albumin nanoparticles as a therapeutic strategy for lung squamous cell carcinoma.Clinical and experimental medicine · 2026Article
- Aptamer-based fluorescence "off-on" sensor for EGFR-positive lung cancer CTCs using streptavidin magnetic beads and N-CQDs@Ag⁺.Mikrochimica acta · 2026Article
- Interleukin-8 in health and disease.Molecular biomedicine · 2026Review
- Targeting lung cancer with tanshinones: Current mechanistic evidence and emerging opportunities (Review).Oncology reports · 2026Review
- miR-2116-5p functions as a tumor suppressor in lung adenocarcinoma by targeting ADAM12 and serves as a prognostic biomarker.Journal of cardiothoracic surgery · 2026Article
- MUC1 promotes the proliferation and invasion of lung cancer cells by regulating PI3K/AKT pathway.Journal of cardiothoracic surgery · 2026Article
- Design synthesis and evaluation of a novel 1,3,4-thiadiazole derivative as a potent anticancer and antibacterial agent supported by electronic property analysis and simulation studies.Scientific reports · 2026Article
- Predictors and characteristics of late recurrence in non-small cell lung cancer patients 5 years or more after complete resection.Surgery today · 2026Article
- Lactylation of β-catenin promotes non-small cell lung cancer by inhibiting ferroptosis through TCF4-mediated GPX4 transcription.Journal of translational medicine · 2026Article
92 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimLung cancer is the leading cause of cancer deaths worldwide. This study examines the current and future burden of lung cancer at global, regional, and national levels.
methodsThe estimates of lung cancer incident cases, deaths, and their age-standardized rates are drawn from GLOBOCAN 2020 for 21 regions and 185 countries. Mortality-to-incidence ratio (MIR) is considered as a proxy indicator of 5-year survival rates. Lung cancer burden in 2050 is projected using age-specific incidence and death rates in 2020.
resultsIn 2020, there were 2.21 million new cases and 1.8 million deaths due to lung cancer worldwide with age-standardized incidence rate (ASIR) of 22.4/100,000 (male: 31.5; female: 14.6) and age-standardized mortality rates (ASMR) of 18.0/100,000, (male: 25.9; female: 11.2/100,000). Global MIR of lung cancer was 0.82 (males 0.83; females: 0.79), varying from 0.59 (Japan) to 1.0 (Belize). Hungary had the highest age-standardized rates (ASIR: 50.1/100,000; ASMR: 42.4/100,000) and Nigeria (ASIR: 0.88; ASMR: 0.86) had the lowest age-standardized rates in 2020. Both ASIR and ASMR were positively correlated with country-level tobacco smoking prevalence and human development index (HDI), whereas MIR exhibited a negative correlation with HDI. As per our projections, there will be 3.8 million incident cases and 3.2 million deaths globally due to lung cancer in 2050.
conclusionWith close to 2 million cases and deaths already in 2020, lung cancer has already become a global public health threat. Even with current risk levels and age-specific rates, lung cancer annual cases are expected to reach 3.8 million in 2050. Until smoking prevalence is reduced and ambient air pollution levels are checked, particularly in low/medium HDI countries, the lung cancer epidemic will continue unfolding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.